Metabolic-associated fatty liver disease and gut microbiota: pathogenetic relationships and therapeutic targets.

Abstract

The article presents the characteristics of metabolically associated fatty liver disease (МАFLD) in combination with intestinal microbiota. The risk factors for the development of МАFLD, the importance of the «microbiotaintestine-liver» axis in the progression of fatty liver disease and in the disruption of the intestinal microbiome with the development of intestinal dysbiosis, which leads to metabolic disorders in the body, are revealed. The use of the drug UDHА (Ursis) and coloprotector Zafacol 3D, which are means of pathogenetic therapy in patients with МАFLD and intestinal dysbiosis, is pathogenetically justified.